Avalon Pharmaceuticals (AVRX) Reports Q1 Loss of $0.37, Misses By 7c
More News related to AVRX
- Avalon Pharmaceuticals (AVRX) Common Stock to be Suspended From Trading
- Clinical Data (CLDA) and Avalon Pharmaceuticals (AVRX) To Merge
- Cantor Fitzgerald Downgrades Avalon Pharmaceuticals (AVRX) to Hold
- Avalon Pharmaceuticals (AVRX) Reports Q1 Loss of $0.37, Misses By 7c
- Avalon Pharmaceuticals (AVRX) Receives Audit Committee Opinion Containing Going Concern Statement
Avalon Pharmaceuticals (Nasdaq: AVRX) reports a Q1 loss of $0.37, 7 cents lower than the analyst estimate of ($0.30). Revenues for the quarter were $50K, versus the consensus of $430K.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
